Skip to Main Content

Recombinant Proteins & Cytokines

Remove risk. Improve performance.

InVitria replaces animal-origin materials with GMP recombinant alternatives to improve performance while removing lot-to-lot variability, regulatory risk, and supply chain fragility in biomanufacturing and final formulation.

>1,000
Active customers across 40+ countries
>600
Customer clinical programs in development
>40
On-market products incorporate InVitria components
7
Approved therapeutics

Trusted Partners

The InVitria platform

Engineered for performance. Quality by design.

Recombinant

  • Animal-origin-free proteins from a non-mammalian system
  • Defined, consistent composition lot to lot
  • Avoid adventitious-agent risk, ready for global filings

Scalable

  • Metric-ton capacity on the ExpressTec™ platform
  • Produced start to finish in the USA
  • Supplied to customers in 40+ countries

Proven

  • Validated in approved therapeutics
  • ISO 9001:2015, cGMP-compliant with complete lot traceability
  • Trusted by Merck, Gilead, Evonik and many others

In the field

Proof, presented.

The data speaks. So do our partners.

Side profile of a scientist pipetting in a biosafety cabinet

Built for your application

The science behind the switch.

Original research, analytical data, and economic modeling from InVitria’s scientific and applications teams.

Contact us

Our team is here to support you.

Lot-specific Certificates of Analysis, application-specific guidance, performance data, and regulatory support.